Drug Profile
Poly-gamma-glutamic acid - BioLeaders Corporation
Alternative Names: BLS-PGA-C10; γ-PGALatest Information Update: 29 May 2023
Price :
$50
*
At a glance
- Originator Bioleaders Corporation
- Developer Bioleaders Corporation; HK inno.N; Tianjin International Joint Academy of Biotechnology and Medicine
- Class Cancer vaccines; Glutamates; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer; COVID 2019 infections
- No development reported Cervical intraepithelial neoplasia
Most Recent Events
- 14 Apr 2023 Preclinical trials in COVID-2019 infections in South Korea (PO) before April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in COVID-2019 infections presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 26 Oct 2022 Preclinical trials in Cancer (Combination therapy) in South Korea before October 2022 (PO)